Literature DB >> 15182098

Advances in screening, diagnosis, and treatment of breast cancer.

Betty A Mincey1, Edith A Perez.   

Abstract

Breast cancer is the most common cancer in women in the United States; this year, approximately 215,900 new cases will be diagnosed. Mammography remains the cornerstone of screening, with technologies such as ultrasonography and magnetic resonance imaging having an increasingly defined role. Improved risk assessment and prevention strategies have been implemented, and current research in these areas includes better identification of patients at risk, the use of aromatase inhibitors and other agents to reduce risk, and the use of surrogate markers. Breast cancer staging has been optimized recently; also, local management of breast cancer, adjuvant systemic therapies, and treatment of patients with advanced disease have been evolving. Advances in screening, diagnosis, and treatment of breast cancer continue to influence our approach to patients with this disease. Many improvements have been made as well in supportive care, including increased tolerability of therapy and notable amelioration of disease symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15182098     DOI: 10.4065/79.6.810

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

Review 1.  Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Authors:  G Pentheroudakis; E Razis; A Athanassiadis; N Pavlidis; G Fountzilas
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain.

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Anna Nardelli; Teresa Pellegrino; Vittorio Simeon; Domenico Gattozzi; Francesca Maddalena; Pierpaolo Mainenti; Giovanni Storto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

3.  A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.

Authors:  Istvan Lang; Gabor Rubovszky; Zsolt Horvath; Erna Ganofszky; Eszter Szabo; Magdolna Dank; Katalin Boer; Erika Hitre
Journal:  J Clin Diagn Res       Date:  2013-06-01

4.  Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer.

Authors:  Yasser Abdel Kader; Marc Spielmann; Tamer El-Nahas; Amr Sakr; Hassan Metwally
Journal:  Breast Cancer (Dove Med Press)       Date:  2013-06-17

5.  Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2005-06-30

6.  Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

Authors:  F Ciardiello; T Troiani; F Caputo; M De Laurentiis; G Tortora; G Palmieri; F De Vita; M R Diadema; M Orditura; G Colantuoni; C Gridelli; G Catalano; S De Placido; A R Bianco
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

7.  A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Authors:  T Sakiyama; J Tsurutani; T Iwasa; H Kawakami; Y Nonagase; T Yoshida; K Tanaka; Y Fujisaka; T Kurata; Y Komoike; K Nishio; K Nakagawa
Journal:  Br J Cancer       Date:  2015-02-05       Impact factor: 7.640

8.  A prospective pilot clinical trial evaluating the utility of a dynamic near-infrared imaging device for characterizing suspicious breast lesions.

Authors:  Ronald X Xu; Donn C Young; Jimmy J Mao; Stephen P Povoski
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.

Authors:  Qamar J Khan; Bruce F Kimler; Anne P O'Dea; Carola M Zalles; Priyanka Sharma; Carol J Fabian
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Optically measured microvascular blood flow contrast of malignant breast tumors.

Authors:  Regine Choe; Mary E Putt; Peter M Carlile; Turgut Durduran; Joseph M Giammarco; David R Busch; Ki Won Jung; Brian J Czerniecki; Julia Tchou; Michael D Feldman; Carolyn Mies; Mark A Rosen; Mitchell D Schnall; Angela DeMichele; Arjun G Yodh
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.